Abimprosyc

Advancing wellness through Abymprosic®, a bioendogenous technology by OGRD Alliance focused on restoring immune system balance. 🧬

[Abimprosyc @abimprosyc]

#ABIMPROSYC
#Biotechnology
#CancerResearch
#PrecisionOncology
#BiomedicalScience
#TranslationalResearch
#LifeSciences
#ScientificInnovation

[Abimprosyc @abimprosyc]

ABIMPROSYC integrates four key biological axes supporting systemic resilience:
1️⃣ Longevity support
2️⃣ Inflammation balance
3️⃣ Immunomodulation
4️⃣ Adaptive recovery
A multi-target perspective on health optimization.
#ABIMPROSYC #SystemsBiology #Immunomodulation #LongevityResearch

[Abimprosyc @abimprosyc]

Read more:
🔗 https://t.co/6K3WdCQx22

[Abimprosyc @abimprosyc]

Real cancer innovation = biological coherence.

🔬 Structure
🧬 Immune balance
📊 Sustainable strategy
#Oncology #Immunotherapy #GlobalHealth

[Abimprosyc @abimprosyc]

For more information:
https://t.co/QOiWemWbug

[Abimprosyc @abimprosyc]

Validation decoupled from systemic exposure.

Ex vivo kinetic profiling + reproducible batch comparability published in Biomedicines (2025, PMID: 41007664).

Supporting SAP/CTD-aligned documentation frameworks.

Full text via DOI.

#Biotech #Oncology #Innovation

[Abimprosyc @abimprosyc]

For more information:
https://t.co/6gczmuzbjb

[Abimprosyc @abimprosyc]

Label-free kinetic tumor profiling now peer-reviewed.

Biology (2025, PMID:40906111).
Captures proliferative divergence & cytokine balance without labeling or co-culture.
Strengthening PLPC-DB™ preclinical rigor.

#Biotech #Oncology

[Abimprosyc @abimprosyc]

For more information:
https://t.co/WMXjpYUdIf

[Abimprosyc @abimprosyc]

Regulatory monitoring framework for DEX immunotherapy published in Int. J. Mol. Sci. (2025, PMID:40564910).

Multistage immune profiling with reproducible Type I–III classification.

Strengthens traceability and positioning of PLPC-DB™.

#Biotech #PrecisionOncology

[Abimprosyc @abimprosyc]

For more information:
https://t.co/L3uINsKrnA

[Abimprosyc @abimprosyc]

Cancers (2025) validates PLPC as an ultrapurified phospholipoproteic complex with improved stability over conventional exosomes.

Structured, reproducible immunobiology.

#PrecisionOncology #Biotech

[Abimprosyc @abimprosyc]

For more information:
https://t.co/ZezLbYbuxu

[Abimprosyc @abimprosyc]

Peer-reviewed validation of PLPC-DB™ platform (2025).
Indexed in PubMed & Web of Science.
Robust proteomic stability.
Preserved immune signaling markers.
Regulatory-ready scalability profile.

Open to strategic collaboration.
#Biotech #Oncology #Innovation

[Abimprosyc @abimprosyc]

For more information:
https://t.co/hQ2nsPGS5X

[Abimprosyc @abimprosyc]

PLPC-DB™ (2025): five peer-reviewed publications supporting traceability, immune profiling, and structural stability.

Built for scalable precision oncology.

#Biotech #PrecisionOncology

[Abimprosyc @abimprosyc]

Not every physiological process requires the same approach.

Support and modulation within biological boundaries are different from clinical intervention.

Understanding when to preserve function — and when to treat pathology — defines responsible innovation.

#HealthStrategy

[Abimprosyc @abimprosyc]

DEX immunotherapy continues advancing through peer-reviewed research.

Recent studies support:
• Phospholipid-rich DC vesicles
• Preserved immune signatures
• Scalable precision platforms
• Structured monitoring
Reproducible immunology.
#DEX #Immunotherapy #Exosomes

[Abimprosyc @abimprosyc]

ecognition follows real clinical work.

Dr. Ramón Gutiérrez was featured among The Most Influential Leaders Transforming Medicine & Oncology Solutions – 2026.

At ABIMPROSYC, we support structured, accountable oncology innovation.

#ABIMPROSYC #Oncology #Immunotherapy